136 related articles for article (PubMed ID: 34125179)
1. Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.
Minderman M; Amir A; Kraan W; Schilder-Tol EJM; Oud MECM; Scheepstra CG; Noorduyn AL; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
Blood; 2021 Sep; 138(13):1194-1197. PubMed ID: 34125179
[No Abstract] [Full Text] [Related]
2. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites.
Riemersma SA; Jordanova ES; Schop RF; Philippo K; Looijenga LH; Schuuring E; Kluin PM
Blood; 2000 Nov; 96(10):3569-77. PubMed ID: 11071656
[TBL] [Abstract][Full Text] [Related]
3. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
[TBL] [Abstract][Full Text] [Related]
6. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.
Shimada K; Yoshida K; Suzuki Y; Iriyama C; Inoue Y; Sanada M; Kataoka K; Yuge M; Takagi Y; Kusumoto S; Masaki Y; Ito T; Inagaki Y; Okamoto A; Kuwatsuka Y; Nakatochi M; Shimada S; Miyoshi H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Shiozawa Y; Nannya Y; Okabe A; Kohno K; Atsuta Y; Ohshima K; Nakamura S; Ogawa S; Tomita A; Kiyoi H
Blood; 2021 Mar; 137(11):1491-1502. PubMed ID: 33512416
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.
Chong LC; Twa DD; Mottok A; Ben-Neriah S; Woolcock BW; Zhao Y; Savage KJ; Marra MA; Scott DW; Gascoyne RD; Morin RD; Mungall AJ; Steidl C
Blood; 2016 Sep; 128(9):1206-13. PubMed ID: 27268263
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
9. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
[TBL] [Abstract][Full Text] [Related]
10. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
12. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
Schonfeld M; Zhao J; Komatz A; Weinman SA; Tikhanovich I
J Biol Chem; 2020 May; 295(20):7126-7137. PubMed ID: 32245889
[TBL] [Abstract][Full Text] [Related]
13. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PI3Kδ Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells.
Ogawa T; Kan-O K; Shiota A; Fujita A; Ishii Y; Fukuyama S; Matsumoto K
Front Immunol; 2021; 12():767666. PubMed ID: 34899719
[TBL] [Abstract][Full Text] [Related]
15. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
16.
Vos L; Dietrich J; Strieth S; Bootz F; Dietrich D; Franzen A
Immunotherapy; 2020 Aug; 12(12):903-920. PubMed ID: 32684057
[No Abstract] [Full Text] [Related]
17. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
18. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
19. [Genetic Alterations Involving PD-L1/PD-L2 in Human Malignancies].
Kataoka K
Gan To Kagaku Ryoho; 2019 May; 46(5):841-844. PubMed ID: 31189800
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]